Acute Kidney Injury (AKI) Market Insights, Epidemiology and Market Forecast, 2027 Featuring Thrasos Therapeutics, AM Pharma, Quark Pharma, Angion Biomedica, Alloksys, LG & Exponential Biotherapies

DUBLIN, Oct 30, 2018 /PRNewswire/ --

The "Acute Kidney Injury (AKI) - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.

Acute Kidney Injury (AKI) - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of AKI in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Acute Kidney Injury (AKI) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Acute Kidney Injury (AKI) - Disease Understanding and Treatment Algorithm

The Acute Kidney Injury (AKI) market report gives the thorough understanding of the Acute Kidney Injury by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Acute Kidney Injury in the US, Europe, and Japan.

Acute Kidney Injury Epidemiology

The Acute Kidney Injury (AKI) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total incident cases, discharge diagnosed cases, stage-wise discharge diagnosed cases, risk factor associated AKI cases and renal transplantation associated delayed graft function cases) scenario of Acute Kidney Injury (AKI) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

According to this research, total incident population of Acute Kidney Injury (AKI) in 7 major markets was found to be 1,516,635 in 2016.

Acute Kidney Injury Drug Chapters

This segment of the Acute Kidney Injury report encloses the detailed analysis of late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Currently there are no targeted pharmacotherapies approved for the treatment of AKI. At present, the therapeutic market size of acute kidney injury is mainly accounted by use of Renal Replacement Therapy (RRT) and off-label drugs which includes various classes such as ACE inhibitors, Angiotensin II-Receptor Blockers (ARBs), Diuretics and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Detailed chapter for upcoming therapies like BB3 (Angion Biomedica), QPI1002 (Quark Pharmaceutical), recAP (AM Pharma), SBI101 (Sentien Biotechnologies), Reltecimod (Ato Bio), THR-184 (Thrasos Therapeutics) (EA230 (Exponential Biotherapies), Simdax (Orion Pharma), and bRESCAP (Alloksys) have been covered in the report.

Acute Kidney Injury Market Outlook

The Acute Kidney Injury market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to this research, the market of Acute Kidney Injury in 7MM was found to be USD 4.3 billion in 2016 and is expected to increase from 2016-2027.

Acute Kidney injury Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Acute Kidney Injury Report Insights

• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Acute Kidney Injury Report Key Strengths

• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Acute Kidney Injury Report Assessment

• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits

• This report will help to develop Business Strategies by understanding the trends shaping and driving Acute Kidney Injury market
• Organize sales and marketing efforts by identifying the best opportunities for Acute Kidney Injury market
• To understand the future market competition in the Acute Kidney Injury market.

Key Topics Covered:

1. Key Insights

2. Acute Kidney Injury Market: Overview at a Glance
2.1. Market Share Distribution of AKI in 2017
2.2. Market Share Distribution of AKI in 2027

3. Acute Kidney Injury (AKI): Disease Background and Overview
3.1. Introduction
3.2. Symptoms
3.3. Types of Acute Kidney Injury
3.4. Stages Classification
3.5. Risk Factors
3.6. Etiology
3.7. Pathophysiology
3.8. Biomarkers
3.9. Diagnosis

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Total Incident Patient Population of AKI
4.3. 7MM Total Discharge Diagnosed Population of AKI

5. Country Wise-Epidemiology of Acute Kidney Injury

6. Current Treatment Practices
6.1. Treatment and Prevention

7. Unmet Needs

8. Emerging Therapies
8.1. Key cross competition- Emerging Therapies
8.2. EA-230: Exponential Biotherapies
8.3. Zemiglo: LG Life Sciences
8.4. bRESCAP: Alloksys
8.5. BB3: Angion Biomedica
8.6. QPI-1002: Quark Pharmaceuticals
8.7. recAP: AM Pharma
8.8. THR-184: Thrasos Therapeutics
8.9. Reltecimod: AtoxBio

9. Acute Kidney Injury: 7 Major Market Analysis
9.1. Key Findings
9.2. Market Size of AKI in 7MM

10. Market Outlook by Country

11. Trends in Cost of Therapies in Acute Kidney Injury

12. Market Drivers

13. Market Barriers

Companies Mentioned

• Thrasos Therapeutics
• AM Pharma
• Quark Pharmaceuticals
• Angion Biomedica
• Alloksys
• LG Life Sciences
• Exponential Biotherapies

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/lfm3px/acute_kidney?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com